Literature DB >> 17849181

Systemic administration of olygodeoxynucleotides with CpG motifs at priming phase reduces local Th2 response and late allergic rhinitis in BALB/c mice.

Toshiharu Hayashi1, Keiko Hasegawa, Yuji Sasaki.   

Abstract

Oligodeoxynucleotides (ODN) with CpG motifs (CpG ODN) induce T helper (Th)1-type reaction. We aimed to evaluate the therapeutic effect of CpG ODN in the development of late allergic rhinitis induced by ovalbumin (OVA), which is one of Th2 diseaes, in BALB/c mice. Effects of a single dose of synthetic CpG-ODN (50 microg) intraperitoneally (i.p.) at the priming phase (on day 0) by OVA on the development of late eosinophilic rhinitis at respiratory areas were compared to the control mice treated with its vehicle (ODN without CpG motifs; 50 microg). Animals were again sensitized by OVA (on day 10) i.p., and 4 days after second sensitization animals were challenged by OVA intranasally (on day 14). Four days after challenge, eosinophilic reactions, nasal lesions and local cytokine values were examined. Compared to the control group, the CpG ODN-administration increased production of OVA-specific Th1 cytokine (interferon-gamma) and decreased productions of ovalubmin-specific Th2 cytokines [interleukin (IL)-5 and IL-13] in nasal cavity fluids, supernatants of splenocytes and/or sera. Also, eosinophilia and increased total IgE values were decreased in mice treated with the CpG ODN compared to the control group. Moreover, nasal lesions with infiltration of eosinophils were prominently reduced by the CpG ODN-treatment compared to the control mice. The present study suggests that the systemic administration of CpG ODN at the priming phase may reduce local OVA-specific Th2 responses, resulting in decreased nasal pathology in the late allergic eosinophilic rhinitis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17849181     DOI: 10.1007/s10753-007-9048-9

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  56 in total

1.  A Toll-like receptor recognizes bacterial DNA.

Authors:  H Hemmi; O Takeuchi; T Kawai; T Kaisho; S Sato; H Sanjo; M Matsumoto; K Hoshino; H Wagner; K Takeda; S Akira
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

2.  Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides.

Authors:  S Sur; J S Wild; B K Choudhury; N Sur; R Alam; D M Klinman
Journal:  J Immunol       Date:  1999-05-15       Impact factor: 5.422

3.  Natural allergen exposure does not influence the density of goblet cells in the nasal mucosa of patients with seasonal allergic rhinitis.

Authors:  G Karlsson; U Pipkorn
Journal:  ORL J Otorhinolaryngol Relat Spec       Date:  1989       Impact factor: 1.538

Review 4.  TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties.

Authors:  T R Mosmann; R L Coffman
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

5.  Mucosal immunity of nasopharynx: an experimental study in TCR-transgenic (OVA23-3) mice.

Authors:  Takaya Yamada; Shingo Kataoka; Keiko Ogasawara; Ryotaro Ishimitsu; Kazuhiro Hashigucci; Tatsuo Suzuki; Hideyuki Kawauchi
Journal:  Rhinology       Date:  2005-09       Impact factor: 3.681

6.  Peripheral blood CD4 but not CD8 t-lymphocytes in patients with exacerbation of asthma transcribe and translate messenger RNA encoding cytokines which prolong eosinophil survival in the context of a Th2-type pattern: effect of glucocorticoid therapy.

Authors:  C J Corrigan; Q Hamid; J North; J Barkans; R Moqbel; S Durham; V Gemou-Engesaeth; A B Kay
Journal:  Am J Respir Cell Mol Biol       Date:  1995-05       Impact factor: 6.914

7.  An antigen-specific hypersensitivity which does not fit into traditional classification of hypersensitivity.

Authors:  H Y Lei; K J Huang; C L Shen; J L Huang
Journal:  J Immunol       Date:  1989-07-15       Impact factor: 5.422

8.  Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.

Authors:  T K Hart; R M Cook; P Zia-Amirhosseini; E Minthorn; T S Sellers; B E Maleeff; S Eustis; L W Schwartz; P Tsui; E R Appelbaum; E C Martin; P J Bugelski; D J Herzyk
Journal:  J Allergy Clin Immunol       Date:  2001-08       Impact factor: 10.793

Review 9.  The role of eosinophils in the pathogenesis of asthma.

Authors:  M C Seminario; G J Gleich
Journal:  Curr Opin Immunol       Date:  1994-12       Impact factor: 7.486

10.  Elimination of CD4+ CD25+ regulatory T cells breaks down reovirus type 2-triggered and CpG ODN-induced prolonged mild autoimmune insulitis in DBA/1 mice.

Authors:  T Hayashi; K Hasegawa; Y Sasaki; T Onodera
Journal:  Scand J Immunol       Date:  2006-02       Impact factor: 3.487

View more
  4 in total

1.  Polarization toward Th1-type response in active, but not in inactive, lupus inhibits late allergic rhinitis in lupus-prone female NZB×NZWF(1) mice.

Authors:  Toshiharu Hayashi; Ayumi Murase
Journal:  Inflammation       Date:  2012-12       Impact factor: 4.092

2.  SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis.

Authors:  Ciriana Orabona; Maria T Pallotta; Claudia Volpi; Francesca Fallarino; Carmine Vacca; Roberta Bianchi; Maria L Belladonna; Maria C Fioretti; Ursula Grohmann; Paolo Puccetti
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-16       Impact factor: 11.205

3.  Acute urticaria[corrected]-like lesions in allergen-unexposed cutaneous tissues in a mouse model of late allergic rhinitis.

Authors:  Toshiharu Hayashi; Taeko Fujii
Journal:  Int J Exp Pathol       Date:  2008-06       Impact factor: 1.925

4.  Nanoparticle conjugation enhances the immunomodulatory effects of intranasally delivered CpG in house dust mite-allergic mice.

Authors:  Marie Ballester; Laura Jeanbart; Alexandre de Titta; Chiara Nembrini; Benjamin J Marsland; Jeffrey A Hubbell; Melody A Swartz
Journal:  Sci Rep       Date:  2015-09-21       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.